Human cytomegalovirus (HCMV, a -herpesvirus) causes lifelong, persistent/latent infection that is largely asymptomatic in healthy persons, but can induce serious disease if host immunity is nave or compromised. HCMV encodes for >170 viral proteins, more than half which function to modulate host innate and adaptive immune defenses. Characterizing the structural and molecular basis of the interactions that occur between these HCMV and host proteins is crucial to facilitate vaccine and antiviral drug development. NK cells are crucial in controlling viral infection and HCMV has evolved several mechanisms to inhibit NK cell activation. In this proposal we will study the gene product UL141, encoded by virulent strains of HCMV, that we hypothesize has evolved to modulate immune signaling networks by targeting both ligands for NK cell receptors, as well as the TNF death receptors. UL141 inhibits expression of TRAIL-DR as well as CD155, an NK cell activating ligand. Together with HCMV gene product US2, UL141 also downregulates CD112, a second ligand for the NK cell activating receptor DNAM-1. In addition, we speculate that UL141 mimics the function of TIGIT, an immunoreceptor that also inhibits NK cell activation. Uncovering how UL141 crosstalks with signaling networks comprised of Ig and TNF family proteins will yield valuable information regarding how these non-canonical binding interactions function to regulate host immunity.

Public Health Relevance

Human Cytomegalovirus (HCMV), a beta-herpesvirus, causes lifelong infection that can lead to serious diseases especially in immune compromised individuals. Almost half of the its viral protein function to inhibit immune responses upon infecting humans and understanding the mechanism by which the virus is able to interact and block the immune system is important in devising strategies aimed at clearing the virus from the body.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI117530-02
Application #
9102891
Study Section
Virology - A Study Section (VIRA)
Program Officer
Lapham, Cheryl K
Project Start
2015-07-01
Project End
2017-06-30
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
La Jolla Institute
Department
Type
DUNS #
603880287
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Dufour, Florent; Rattier, Thibault; Shirley, Sarah et al. (2017) N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death. Cell Death Differ 24:500-510